WilmerHale Reps Achillion Pharmaceuticals in Pricing of Secondary Offering of Common Stock

WilmerHale Reps Achillion Pharmaceuticals in Pricing of Secondary Offering of Common Stock

Firm News

Achillion Pharmaceuticals, Inc. announced the pricing of an underwritten public offering of 18,367,346 shares of its common stock by existing stockholder Johnson & Johnson Innovation-JJDC, Inc., which shares constitute all of JJDC's equity position in Achillion, at a public offering price of $2.75 per share. The offering is expected to close on November 20, 2017.

The WilmerHale deal team representing Achillion includes Steven Singer, Cynthia Mazareas, Scott Lunin and Killian Nolan.

Read Achillion's press release for more details.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.